

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptalxn1621

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 14:08:31 ON 27 NOV 2006

=> ....Testing the current file.... screen

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Please change to a suitable file and repeat your upload

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 14:09:32 ON 27 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 NOV 2006 HIGHEST RN 913953-45-4

DICTIONARY FILE UPDATES: 26 NOV 2006 HIGHEST RN 913953-45-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> ....Testing the current file.... screen


ENTER SCREEN EXPRESSION OR (END):end

=> screen 2076

L1 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10649762.str



```

chain nodes :
7 8 9 10 11 12 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
35 36
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
4-7 6-9 7-8 9-10 10-11 10-12 12-13 12-19 16-20 17-34 20-24 20-21 21-22
21-23 22-36 22-30 22-25 25-26 26-27 26-35 27-28 27-29 30-31 30-33 31-32
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
4-7 10-12 12-19 20-24 20-21 21-22 26-27 27-29
exact bonds :
6-9 7-8 9-10 10-11 12-13 16-20 17-34 21-23 22-36 22-30 22-25 25-26
26-35 27-28 31-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 30-31
30-33

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom
36:Atom

```

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 QUE L2 AND L1

=> d L3

L3 HAS NO ANSWERS

L1 SCR 2076

L2 STR



=> s L4

L5 2 L4

=> d L5 1-2 bib abs

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:260225 CAPLUS

DN 132:294010

TI Preparation of diaminopropionic acid derivatives as intracellular adhesion molecule-1 (ICAM-1) binding inhibitors

IN Fotouhi, Nader; Gillespie, Paul; Guthrie, Robert William; Pietranico-Cole, Sherrie Lynn; Yun, Weiya

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 259 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021920	A1	20000420	WO 1999-EP7620	19991012
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6331640	B1	20011218	US 1999-407534	19990929
	CA 2344058	AA	20000420	CA 1999-2344058	19991012
	BR 9914602	A	20010703	BR 1999-14602	19991012
	EP 1121342	A1	20010808	EP 1999-953772	19991012
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	TR 200101038	T2	20010921	TR 2001-200101038	19991012
	JP 2002527416	T2	20020827	JP 2000-575829	19991012
	JP 3720709	B2	20051130		
	AU 766468	B2	20031016	AU 2000-10349	19991012
	ZA 2001002608	A	20020930	ZA 2001-2608	20010329
	US 2002052512	A1	20020502	US 2001-879700	20010612
	US 2004006236	A1	20040108	US 2003-349289	20030122
	US 6803384	B2	20041012		
	US 2005080119	A1	20050414	US 2004-945650	20040921
PRAI	US 1998-104120P	P	19981013		
	US 1999-407534	A3	19990929		
	WO 1999-EP7620	W	19991012		
	US 2001-879700	B3	20010612		
	US 2003-349289	A3	20030122		
OS	MARPAT 132:294010				
GI					



I

AB Diaminopropionic acid derivs. I [R1 = substituted 1-naphthyl, 4-indolyl,

4-benzimidazolyl, 4-benzodiazolyl, 4-benzotriazolyl, or phenyl; R2 = CHR3NHCO (R3 = H, carboxy, alkyl), CH2CH2CO, 1,2-cyclopropanediylcarbonyl, OCH2CO, CH:CHCHR3, CH2CH2CH(OH), CONHCHR3, or CH2NH-5,1-tetrazolediyl; U, V, W = H, halo, alkyl provided that U and V are not both hydrogen; X = CO, phenylalkylene, sulfonyl; Y = alkylene which may be substituted by amino or cycloalkyl, alkenylene, alkylenethio; Z = H, alkylthio, CO2H, CONH2, 1-adamantyl, diphenylmethyl, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-2-pyrazinyl, hydroxy, phenylmethoxy, 2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]phenyl, [(2,6-dichlorophenyl)methoxy], Ph, (un)substituted cycloalkyl or aryl or fused ring system which may contain 0-3 heteroatoms; m, n = 0, 1] or their pharmaceutically acceptable salts or esters were prepared and are useful for treating rheumatoid arthritis, psoriasis, multiple sclerosis, Crohn's disease, ulcerative colitis, atherosclerosis, restenosis, pancreatitis, transplant rejection, delayed graft function and diseases of ischemia reperfusion injury, including acute myocardial infarction and stroke. Thus, N-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-(3-methoxybenzoylamino)-L-alanine was prepared by the solid-phase method and showed IC50 = 1.2 nM in the LFA-1 (lymphocyte function-associated antigen-1)/ICAM-1 protein-protein assay.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:640697 CAPLUS  
DN 131:267045  
TI Peptidomimetic antagonists for treatment of CD11/CD18 adhesion  
receptor-mediated disorders  
IN Burdick, Daniel J.  
PA Genentech, Inc., USA  
SO PCT Int. Appl., 230 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9949856	A2	19991007	WO 1999-US6410	19990324
	WO 9949856	A3	19991118		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
	TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				
	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				
	CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2325986	AA	19991007	CA 1999-2325986	19990324
	AU 9931137	A1	19991018	AU 1999-31137	19990324
	AU 764524	B2	20030821		
	EP 1063982	A2	20010103	EP 1999-912869	19990324
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	HU 200101587	A2	20010828	HU 2001-1587	19990324
	BR 9909418	A	20010925	BR 1999-9418	19990324
	NZ 506779	A	20030829	NZ 1999-506779	19990324
	ZA 2000004653	A	20011211	ZA 2000-4653	20000905
	NO 2000004800	A	20001124	NO 2000-4800	20000926
	US 2005203135	A1	20050915	US 2003-649762	20030826
PRAI	US 1998-79732P	P	19980327		
	WO 1999-US6410	W	19990324		
	US 2000-646330	B1	20000914		

OS MARPAT 131:267045

AB Peptidomimetic compds. (Markush included) that are useful for treating Mac-1- or LFA-1-mediated disorders, e.g. inflammatory disorders, allergies,

and autoimmune diseases, are provided.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

6.40

173.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

-1.50

-1.50

STN INTERNATIONAL LOGOFF AT 14:11:23 ON 27 NOV 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptalxnl621

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may



result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:14:49 ON 27 NOV 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:15:03 ON 27 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 NOV 2006 HIGHEST RN 913953-45-4

DICTIONARY FILE UPDATES: 26 NOV 2006 HIGHEST RN 913953-45-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> ....Testing the current file.... screen



ENTER SCREEN EXPRESSION OR (END):end

=> screen 2076

L1 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10649762A.str



```

chain nodes :
7  8  9  10  11  12  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34
 35  36
ring nodes :
1  2  3  4  5  6  13  14  15  16  17  18
chain bonds :
4-7  6-9  7-8  9-10  10-11  10-12  12-13  12-19  16-20  17-34  20-24  20-21  21-22
21-23  22-36  22-30  22-25  25-26  26-27  26-35  27-28  27-29  30-31  30-33  31-32
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  13-14  13-18  14-15  15-16  16-17  17-18
exact/norm bonds :
4-7  10-12  12-19  20-24  20-21  21-22  26-27  27-28  27-29
exact bonds :
6-9  7-8  9-10  10-11  12-13  16-20  17-34  21-23  22-36  22-30  22-25  25-26
26-35  31-32
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  13-14  13-18  14-15  15-16  16-17  17-18  30-31
30-33

```

G1:Hy,Cb,Cy,Ak

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom
36:Atom

```

L2 STRUCTURE UPLOADED

=> que L2 AND L1


L3 QUE L2 AND L1

=> D L3

L3 HAS NO ANSWERS

L1 SCR 2076

L2 STR



G1 Hy,Cb,Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

L3 QUE ABB=ON PLU=ON L2 AND L1

=> s L3

SAMPLE SEARCH INITIATED 14:15:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 44 TO ITERATE

100.0% PROCESSED 44 ITERATIONS  
SEARCH TIME: 00.00.01

13 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 483 TO 1277  
PROJECTED ANSWERS: 44 TO 476

L4 13 SEA SSS SAM L2 AND L1

=> s L4 full

FULL SEARCH INITIATED 14:15:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 722 TO ITERATE

100.0% PROCESSED 722 ITERATIONS  
SEARCH TIME: 00.00.01

251 ANSWERS

L5 251 SEA SSS FUL L2 AND L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 14:15:56 ON 27 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Nov 2006 VOL 145 ISS 23  
FILE LAST UPDATED: 26 Nov 2006 (20061126/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L5

L6 8 L5

=> d L6 1-8 bib abs

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:931104 CAPLUS  
DN 145:433596  
TI Regulation of outside-in signaling and affinity by the  $\beta 2$  I domain of integrin  $\alpha L\beta 2$   
AU Chen, JianFeng; Yang, Wei; Kim, Minsoo; Carman, Christopher V.; Springer, Timothy A.  
CS CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, MA, 02115, USA  
SO Proceedings of the National Academy of Sciences of the United States of America (2006), 103(35), 13062-13067  
CODEN: PNASA6; ISSN: 0027-8424  
PB National Academy of Sciences  
DT Journal  
LA English  
AB The adhesiveness of integrin  $\alpha L\beta 2$  is modulated by divalent cations. We mutated three metal ion-binding sites in the  $\beta 2$  I domain. The metal ion-dependent adhesion site (MIDAS) and the ligand-induced metal-binding site are required for ligand binding and sufficient for synergism between  $Ca^{2+}$  and  $Mg^{2+}$ . Adjacent to MIDAS (ADMIDAS) mutants are constitutively active but remain bent, with poor exposure of a  $\beta 2$  stalk region epitope. Fluorescence resonance energy transfer between fluorescent protein-fused  $\alpha L$  and  $\beta 2$  cytoplasmic domains showed that ADMIDAS mutation abrogated ligand binding-induced spatial separation of cytoplasmic domains. Furthermore, ADMIDAS mutation abolished spreading on ligand-bearing substrates. Thus,  $\beta 2$  I domain metal ion-binding sites regulate  $\alpha L$  I domain affinity, and the ADMIDAS is required for outside-in signaling.  
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1262237 CAPLUS  
DN 144:35272  
TI Augmenting B cell depletion by promoting intravascular access  
IN Chan, Andrew C.; Gong, Qian; Martin, Flavius  
PA Genentech, Inc., USA  
SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113003	A2	20051201	WO 2005-US12984	20050415
	WO 2005113003	A3	20060316		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005244751	A1	20051201	AU 2005-244751	20050415
	US 2005276803	A1	20051215	US 2005-107028	20050415
PRAI	US 2004-563263P	P	20040416		
	WO 2005-US12984	W	20050415		

OS MARPAT 144:35272

AB The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. Certain B lymphocytes residing in tissues and organs, in particular those in the marginal zone of the spleen, are resistant to killing with anti-human CD20 antibody, even though these cells express sufficient levels of CD20 on their surface and are sats. with the administered anti-CD20 antibody. Promoting the egress of these B cells from the tissues in which they are resident into the vascular system and/or prolonging their presence in circulation renders them sensitive to killing by the anti-CD20 antibody. On approach to improving intravascular access of these sequestered B cells is to mobilize them into the circulation with antagonists of integrins that tether these B cells to certain zones in the lymphoid tissues. Thus, B cell mobilizing agents may comprise antibodies binding to the integrin  $\alpha 4$  subunit (in  $\alpha 4\beta 1$  or  $\alpha 4\beta 7$ ) or  $\alpha L$  subunit ( $\alpha L\beta 2$ ), or small mol. antagonists of  $\alpha 4$  or  $\alpha L$ . Depletion of the mobilized B cells is achieved using antagonists of B cell surface markers (CD20, CD22, CD52). Methods of treating B cell disorders by this approach are also provided, including B cell neoplasms and autoimmune diseases.

L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:409652 CAPLUS

DN 142:441860

TI Use of statin to kill EBV-transformed B cells

IN Cohen, Jeffrey I.; Pesnicak, Lesley; Katano, Harutaka

PA The Government of the United States of America, as Represented by the Secretary Department of Health and Human Services, USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042710	A1	20050512	WO 2004-US35829	20041028
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

PRAI US 2003-515013P P 20031028

AB Simvastatin, other LFA-1 inhibiting statins, and LFA-1 inhibiting  
statin-derived and statin-like compds., are useful for treatment or  
prevention of V-associated (or herpes virus-associated or other  
virus-associated)  
tumors, including lymphomas and carcinomas, expressing LFA-1 and  
transforming proteins.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:779059 CAPLUS

DN 139:390970

TI Small molecule integrin antagonists that bind to the  $\beta 2$  subunit  
I-like domain and activate signals in one direction and block them in the  
other

AU Shimaoka, Motomu; Salas, Azucena; Yang, Wei; Weitz-Schmidt, Gabriele;  
Springer, Timothy A.

CS The CBR Institute for Biomedical Research and Department of Anesthesia and  
Pathology, Harvard Medical School, Boston, MA, 02115, USA

SO Immunity (2003), 19(3), 391-402  
CODEN: IUNIEH; ISSN: 1074-7613

PB Cell Press

DT Journal

LA English

AB Leukocyte integrins contain an inserted (I) domain in their  $\alpha$   
subunits and an I-like domain in their  $\beta 2$  subunit, which directly  
bind ligand and regulate ligand binding, resp. The authors describe a  
novel mechanistic class of integrin inhibitors that bind to the metal  
ion-dependent adhesion site of the  $\beta 2$  I-like domain and prevent its  
interaction with and activation of the  $\alpha L$  I domain. The inhibitors  
do not bind to the  $\alpha L$  I domain but stabilize  $\alpha/\beta$  subunit  
association and can show selectivity for  $\alpha L\beta 2$  compared to  
 $\alpha M\beta 2$ . The inhibitors reveal a crucial intersection for  
relaying conformational signals within integrin extracellular domains.  
While blocking signals in one direction to the I domain, the antagonists  
induce the active conformation of the I-like domain and stalk domains, and  
thus transmit conformational signals in the other direction toward the  
transmembrane domains.

RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:248720 CAPLUS

DN 137:139288

TI Small molecule inhibitors induce conformational changes in the I domain  
and the I-like domain of lymphocyte function-associated antigen-1:  
molecular insights into integrin inhibition

AU Welzenbach, Karl; Hommel, Ulrich; Weitz-Schmidt, Gabriele

CS Preclinical Research, Novartis Pharma AG, Basel, CH-4002, Switz.

SO Journal of Biological Chemistry (2002), 277(12), 10590-10598  
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB The  $\beta 2$  integrin lymphocyte function-associated antigen-1 (LFA-1) is a  
conformationally flexible  $\alpha/\beta$  heterodimeric receptor, which is  
expressed on the surface of all leukocytes. LFA-1 mediates cell adhesion

crucial for normal immune and inflammatory responses. Intracellular signals or cations are required to convert LFA-1 from a non-ligand binding to a ligand binding state. Here the authors investigated the effect of small mol. inhibitors on LFA-1 by monitoring the binding of monoclonal antibodies mapped to different receptor domains. The inhibitors were found to not only induce epitope changes in the I domain of the  $\alpha$ L chain but also in the I-like domain of the  $\beta$ 2 chain depending on the individual chemical structure of the inhibitor and its binding site. For the first time, the authors provide strong evidence that the I-like domain represents a target for allosteric LFA-1 inhibition similar to the well established regulatory L-site on the I domain of LFA-1. Moreover, the antibody binding patterns observed in the presence of the various inhibitors establish a conformational interaction between the LFA-1 I domain and the I-like domain in the native receptor that is formed upon activation. Differentially targeting the binding sites of the inhibitors, the L-site and the I-like domain, may open new avenues for highly specific therapeutic intervention in diseases where integrins play a pathophysiol. role.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:489264 CAPLUS  
DN 135:97446  
TI Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)  
IN Bentley, Michael David; Zhao, Xuan  
PA Shearwater Corporation, USA  
SO PCT Int. Appl., 36 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047562	A2	20010705	WO 2000-US33581	20001208
	WO 2001047562	A3	20020912		
	WO 2001047562	C1	20031023		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6413507	B1	20020702	US 1999-469418	19991223
	CA 2394716	AA	20010705	CA 2000-2394716	20001208
	EP 1259262	A1	20021127	EP 2000-984208	20001208
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003518526	T2	20030610	JP 2001-548150	20001208
	AU 782032	B2	20050630	AU 2001-20869	20001208
	US 2001027212	A1	20011004	US 2001-842976	20010426
	US 6461602	B2	20021008		
	US 2001046481	A1	20011129	US 2001-842514	20010426
	US 6541015	B2	20030401		
	US 6514491	B1	20030204	US 2001-842977	20010426
	US 2004013637	A1	20040122	US 2003-361451	20030210
	US 6899867	B2	20050531		
	US 2005147583	A1	20050707	US 2005-33547	20050110
	US 7060259	B2	20060613		
	US 2006193823	A1	20060831	US 2006-414456	20060428
PRAI	US 1999-469418	A	19991223		

WO 2000-US33581 W 20001208  
 US 2001-842514 A1 20010426  
 US 2003-361451 A1 20030210  
 US 2005-33547 A1 20050110

AB Poly(ethylene glycol) carbamate derivs. useful as water-soluble prodrugs are disclosed. These degradable poly(ethylene glycol) carbamate derivs. also have potential applications in controlled hydrolytic degradation of hydrogels. In such degradable hydrogels, drugs may be either trapped in the gel and released by diffusion as the gel degrades, or they may be covalently bound through hydrolyzable carbamate linkages. Hydrolysis of these carbamate linkages releases the amine drug at a controllable rate as the gel degrades. Lysozyme was treated with mPEG Ph ether p-succinimidyl carbonate (preparation given) to give a conjugate, which showed a controlled release of free lysozyme upon hydrolysis.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:260225 CAPLUS

DN 132:294010

TI Preparation of diaminopropionic acid derivatives as intracellular adhesion molecule-1 (ICAM-1) binding inhibitors

IN Fotouhi, Nader; Gillespie, Paul; Guthrie, Robert William; Pietranico-Cole, Sherrie Lynn; Yun, Weiya

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 259 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021920	A1	20000420	WO 1999-EP7620	19991012
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6331640	B1	20011218	US 1999-407534	19990929
	CA 2344058	AA	20000420	CA 1999-2344058	19991012
	BR 9914602	A	20010703	BR 1999-14602	19991012
	EP 1121342	A1	20010808	EP 1999-953772	19991012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101038	T2	20010921	TR 2001-200101038	19991012
	JP 2002527416	T2	20020827	JP 2000-575829	19991012
	JP 3720709	B2	20051130		
	AU 766468	B2	20031016	AU 2000-10349	19991012
	ZA 2001002608	A	20020930	ZA 2001-2608	20010329
	US 2002052512	A1	20020502	US 2001-879700	20010612
	US 2004006236	A1	20040108	US 2003-349289	20030122
	US 6803384	B2	20041012		
	US 2005080119	A1	20050414	US 2004-945650	20040921
PRAI	US 1998-104120P	P	19981013		
	US 1999-407534	A3	19990929		
	WO 1999-EP7620	W	19991012		
	US 2001-879700	B3	20010612		
	US 2003-349289	A3	20030122		

OS MARPAT 132:294010

GI





AB Diaminopropionic acid derivs. I [R1 = substituted 1-naphthyl, 4-indolyl, 4-benzimidazolyl, 4-benzodiazolyl, 4-benzotriazolyl, or phenyl; R2 = CHR3NHCO (R3 = H, carboxy, alkyl), CH2CH2CO, 1,2-cyclopropanediylcarbonyl, OCH2CO, CH:CHCHR3, CH2CH2CH(OH), CONHCHR3, or CH2NH-5,1-tetrazolediyl; U, V, W = H, halo, alkyl provided that U and V are not both hydrogen; X = CO, phenylalkylene, sulfonyl; Y = alkylene which may be substituted by amino or cycloalkyl, alkenylene, alkylene thio; Z = H, alkylthio, CO2H, CONH2, 1-adamantyl, diphenylmethyl, 3-[[[(5-chloro-2-pyridinyl)amino]carbonyl]-2-pyrazinyl, hydroxy, phenylmethoxy, 2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]phenyl, [(2,6-dichlorophenyl)methoxy], Ph, (un)substituted cycloalkyl or aryl or fused ring system which may contain 0-3 heteroatoms; m, n = 0, 1] or their pharmaceutically acceptable salts or esters were prepared and are useful for treating rheumatoid arthritis, psoriasis, multiple sclerosis, Crohn's disease, ulcerative colitis, atherosclerosis, restenosis, pancreatitis, transplant rejection, delayed graft function and diseases of ischemia reperfusion injury, including acute myocardial infarction and stroke. Thus, N-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-(3-methoxybenzoylamino)-L-alanine was prepared by the solid-phase method and showed IC50 = 1.2 nM in the LFA-1 (lymphocyte function-associated antigen-1)/ICAM-1 protein-protein assay.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:640697 CAPLUS  
DN 131:267045  
TI Peptidomimetic antagonists for treatment of CD11/CD18 adhesion  
receptor-mediated disorders  
IN Burdick, Daniel J.  
PA Genentech, Inc., USA  
SO PCT Int. Appl., 230 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9949856	A2	19991007	WO 1999-US6410	19990324
	WO 9949856	A3	19991118		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
	TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				
	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				
	CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2325986	AA	19991007	CA 1999-2325986	19990324
	AU 9931137	A1	19991018	AU 1999-31137	19990324
	AU 764524	B2	20030821		
	EP 1063982	A2	20010103	EP 1999-912869	19990324
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

HU 200101587	A2	20010828	HU 2001-1587	19990324
BR 9909418	A	20010925	BR 1999-9418	19990324
NZ 506779	A	20030829	NZ 1999-506779	19990324
ZA 2000004653	A	20011211	ZA 2000-4653	20000905
NO 2000004800	A	20001124	NO 2000-4800	20000926
US 2005203135	A1	20050915	US 2003-649762	20030826
PRAI US 1998-79732P	P	19980327		
WO 1999-US6410	W	19990324		
US 2000-646330	B1	20000914		

OS MARPAT 131:267045

AB Peptidomimetic compds. (Markush included) that are useful for treating Mac-1- or LFA-1-mediated disorders, e.g. inflammatory disorders, allergies, and autoimmune diseases, are provided.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	22.38	189.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.00	-6.00

STN INTERNATIONAL LOGOFF AT 14:16:29 ON 27 NOV 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptalxnl621

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAPLUS patent kind codes will be updated
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may